文献速递性腺与生殖内分泌

睾酮治疗不影响男性性腺功能减退症患者的凝血:基于凝血酶生成的纵向研究

Testosterone Therapy Does Not Affect Coagulation in Male Hypogonadism: A Longitudinal Study Based on Thrombin Generation.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

这项在2个三级内分泌门诊中心开展的前瞻性观察性队列研究纳入38例性腺功能减退症男性和38例年龄匹配的健康对照,比较启动睾酮替代治疗前(T0)与6个月后(T1)的整体凝血功能。结果显示T0至T1凝血酶生成试验参数无变化,性腺功能减退症男性在T0和T1均表现为凝血酶生成潜力、纤维蛋白原显著高于健康对照、抗凝血酶显著低于健康对照。作者认为短期睾酮替代治疗不恶化整体凝血,该治疗可安全用于确诊性腺功能减退症的男性。

要点

  • 性腺功能减退症男性较健康对照存在促凝失衡,表现为凝血酶生成潜力升高。
  • 启动睾酮替代治疗6个月前后,凝血酶生成试验各参数未见变化。
  • 短期睾酮替代治疗不恶化整体凝血,作者认为可安全用于确诊患者。

核心结论

  • 性腺功能减退症男性存在以凝血酶生成增加为表现的促凝失衡;短期睾酮替代治疗不恶化整体凝血,提示该治疗可安全用于确诊性腺功能减退症的男性。

研究设计与样本

  • 前瞻性观察性队列研究,在2个三级内分泌门诊中心开展。
  • 纳入38例性腺功能减退症男性(平均年龄55岁,标准差13)和38例年龄匹配的健康对照。
  • 在性腺功能减退症男性启动睾酮替代治疗前(T0)和6个月后(T1)以及健康对照中行凝血酶生成试验,并检测蛋白C、抗凝血酶、凝血因子VIII和纤维蛋白原。

主要发现

  • 性腺功能减退症男性T0至T1凝血酶生成试验参数无变化。
  • 性腺功能减退症男性在T0和T1凝血酶生成潜力、纤维蛋白原均显著高于健康对照,抗凝血酶显著低于健康对照。
  • 性腺功能减退症男性凝血酶峰值在T0显著高于健康对照,在T1则无显著差异。
  • 凝血酶生成潜力与抗凝血酶均与睾酮水平相关。

临床怎么用

  • 作者认为短期睾酮替代治疗不恶化整体凝血,可安全用于确诊性腺功能减退症的男性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Testosterone therapy has been variably associated with increased thrombotic risk but investigations of global coagulation in this setting are lacking. OBJECTIVE: This work aimed to compare global coagulation of hypogonadal men before (T0) and 6 months after (T1) starting testosterone replacement therapy (TRT), and healthy controls (HCs). METHODS: An observational prospective cohort study was conducted at 2 tertiary endocrinological ambulatory care centers. Patients included 38 men with hypogonadism (mean age 55 years, SD 13) and 38 age-matched HCs. Thrombin generation assay (TGA) was performed at T0 and T1 in hypogonadal men and in HCs. TGA is an in vitro procedure based on the continuous registration of thrombin generation and decay under conditions mimicking the process that occurs in vivo. The following TGA parameters were recorded: lag time; thrombin-peak concentration; time-to-reach peak, velocity index, and endogenous thrombin potential (ETP), the latter representing the total amount of thrombin generated under the driving forces of procoagulants opposed by the anticoagulants. Protein C, antithrombin, factor (F) VIII, and fibrinogen were assessed. RESULTS: No changes in TGA parameters were observed between T0 and T1. Hypogonadal men displayed significantly higher ETP, fibrinogen, and significantly lower antithrombin levels both at T0 and T1 compared to HCs. Thrombin peak of hypogonadal men was significantly higher than HCs at T0 but not at T1. ETP and antithrombin were correlated with testosterone levels. CONCLUSION: Hypogonadal men display a procoagulant imbalance detected by increased thrombin generation. Short-term TRT does not worsen global coagulation, suggesting that the treatment can be safely prescribed to men diagnosed with hypogonadism.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lanzi V, Indirli R, Tripodi A, et al. Testosterone Therapy Does Not Affect Coagulation in Male Hypogonadism: A Longitudinal Study Based on Thrombin Generation. J Clin Endocrinol Metab. 2024. PMID: 38717871. doi:10.1210/clinem/dgae317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。